Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.20 | N/A | -0.08% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.20 | N/A | -0.08% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance. They highlighted ongoing market challenges but did not provide detailed forecasts.
Management did not provide specific guidance for the upcoming quarters.
The company acknowledged challenges in the current market environment.
AbbVie's earnings report showed a slight miss on EPS, which contributed to a 2.07% decline in stock price. The lack of revenue figures and guidance may have added to investor uncertainty. Overall, the cautious tone from management suggests that the company is facing challenges that could impact future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TEXAS INSTRS INC
Jan 24, 2017